TMDX
BULLISH
$113.13
Live
TransMedics Group, Inc. · NASDAQ
Target $155.0
(+37.0%)
$88.0
52W Range
$156.0
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 21, 2026
Market cap
$3.91B
P/E
23.28
ROE
54.2%
Profit margin
31.4%
Debt/Equity
1.1
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
75%
TMDX exhibits a stable financial health profile with a Piotroski F-Score of 4/9 and exceptional liquidity (Current Ratio 7.14). While the Graham Number ($38.85) suggests significant overvaluation from a defensive standpoint, the growth-based intrinsic value of $143.37 indicates the current price of $113.13 is an attractive entry point for growth investors. The company has successfully transitioned from consistent losses to explosive earnings growth and high profitability (ROE 54.24%). Despite bearish insider sentiment and technicals, the fundamental trajectory and analyst consensus remain strongly positive.
Key Strengths
Explosive earnings growth (YoY 1188.10%) reflecting a successful pivot to profitability
Exceptional liquidity with a Current Ratio of 7.14 and Quick Ratio of 6.41
Strong profitability metrics including a 31.43% profit margin and 54.24% ROE
Consistent track record of beating earnings estimates (3/4 last quarters)
Robust revenue growth of 32.20% YoY
Key Risks
Bearish insider activity with 9 sell transactions and 0 buys in the last 6 months
Technical trend is currently 0/100, indicating strong short-term bearish momentum
High Price-to-Book ratio (8.19) suggests a premium valuation
Forward P/E (30.71) is higher than trailing P/E (23.28), suggesting a potential slowdown in earnings growth rate
Concentration risk inherent in specialized medical device industries
AI Fair Value Estimate
Based on comprehensive analysis
$138.22
+22.2% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
58
Moderate
55
90
85
60
0
AI Verdict
Strong Growth Play
Key drivers: Earnings inflection point, High ROE, Strong liquidity, Revenue scaling
Confidence
80%
Value
55/100
P/E 23.28; Graham Number $38.85; Intrinsic Value $143.37
Positives
- P/E is reasonable for the growth rate
Watchpoints
- Trades far above Graham Number
- High P/B ratio
Future
90/100
YoY Revenue Growth 32.20%
Positives
- 32% Revenue growth
- Strong analyst target price of $155
Watchpoints
- Forward P/E expansion
Past
85/100
Earnings growth 1188.10% YoY
Positives
- Successful transition from negative to positive EPS
- Consistent earnings surprises
Watchpoints
- Historical losses prior to 2023
Health
60/100
Piotroski F-Score 4/9; Altman Z-Score N/A
Positives
- Very high current ratio (7.14)
- Stable Piotroski score
Watchpoints
- Debt/Equity at 1.10
- Piotroski F-Score is only 4/9
Dividend
0/100
Dividend Yield N/A
Positives
No standout positives identified.
Watchpoints
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$113.13
Analyst Target
$155.0
Upside/Downside
+37.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for TMDX and closest competitors.
Updated 2026-04-20
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
TMDX
TransMedics Group, Inc.
Primary
|
+298.9% | +27.5% | +29.0% | -5.7% | -0.7% | -0.2% |
|
NAMS
NewAmsterdam Pharma Company N.V.
Peer
|
+246.8% | +157.0% | +109.7% | -9.0% | +15.6% | +1.6% |
|
ALHC
Alignment Healthcare, Inc.
Peer
|
+11.0% | +93.4% | +42.7% | +17.5% | -12.9% | -6.7% |
|
INDV
Indivior Pharmaceuticals, Inc.
Peer
|
+218.1% | +75.0% | +241.6% | +28.4% | -7.0% | +0.2% |
|
MMED
Minimed Group, Inc.
Peer
|
-22.2% | -22.2% | -22.2% | -22.2% | -8.7% | +8.8% |
TMD
TransMedics Group, Inc.
Primary
5Y
+298.9%
3Y
+27.5%
1Y
+29.0%
6M
-5.7%
1M
-0.7%
1W
-0.2%
NAM
NewAmsterdam Pharma Company N.V.
Peer
5Y
+246.8%
3Y
+157.0%
1Y
+109.7%
6M
-9.0%
1M
+15.6%
1W
+1.6%
ALH
Alignment Healthcare, Inc.
Peer
5Y
+11.0%
3Y
+93.4%
1Y
+42.7%
6M
+17.5%
1M
-12.9%
1W
-6.7%
IND
Indivior Pharmaceuticals, Inc.
Peer
5Y
+218.1%
3Y
+75.0%
1Y
+241.6%
6M
+28.4%
1M
-7.0%
1W
+0.2%
MME
Minimed Group, Inc.
Peer
5Y
-22.2%
3Y
-22.2%
1Y
-22.2%
6M
-22.2%
1M
-8.7%
1W
+8.8%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
23.28
Forward P/E
30.71
PEG Ratio
N/A
P/B Ratio
8.19
P/S Ratio
6.45
EV/Revenue
6.46
EV/EBITDA
29.09
Market Cap
$3.91B
Profitability
Profit margins and return metrics
Profit Margin
31.43%
Operating Margin
13.23%
Gross Margin
59.92%
ROE
54.24%
ROA
7.25%
Growth
Revenue and earnings growth rates
Revenue Growth
+32.2%
Earnings Growth
+1188.1%
Q/Q Revenue Growth
+32.18%
Q/Q Earnings Growth
+1436.9%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.1
Moderate
Current Ratio
7.14
Strong
Quick Ratio
6.41
Excellent
Cash/Share
$14.24
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.2B
Gross Margin
58.1%
Op. Margin
13.2%
Net Margin
65.6%
Total Assets
$1.1B
Liabilities
$0.6B
Equity
$0.5B
Debt/Equity
1.26x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
55%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-24
$0.53
+41.0% surprise
2025-10-29
$0.66
+83.3% surprise
2025-07-30
$0.92
+114.8% surprise
Healthcare Sector Comparison
Comparing TMDX against 498 companies in the Healthcare sector
(28 bullish, 153 neutral, 317 bearish)
P/E Ratio
23.28
This Stock
vs
84.2
Sector Avg
-72.4%
(Discount)
Return on Equity (ROE)
54.24%
This Stock
vs
-95.47%
Sector Avg
-156.8%
(Below Avg)
Profit Margin
31.43%
This Stock
vs
-15.87%
Sector Avg
-298.0%
(Weaker)
Debt to Equity
1.1
This Stock
vs
2.89
Sector Avg
-62.0%
(Less Debt)
Revenue Growth
32.2%
This Stock
vs
137.48%
Sector Avg
-76.6%
(Slower)
Current Ratio
7.14
This Stock
vs
4.66
Sector Avg
+53.2%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
TMDX
TransMedics Group, Inc.
|
BULLISH | $3.91B | 23.28 | 54.2% | 31.4% | $113.13 | |
|
NAMS
NewAmsterdam Pharma Company N.V.
|
BEARISH | $3.96B | - | -28.3% | -% | $34.44 | Compare |
|
ALHC
Alignment Healthcare, Inc.
|
BEARISH | $3.85B | - | -0.7% | -0.0% | $19.22 | Compare |
|
INDV
Indivior Pharmaceuticals, Inc.
|
NEUTRAL | $3.82B | 18.62 | -% | 16.9% | $30.54 | Compare |
|
MMED
Minimed Group, Inc.
|
NEUTRAL | $4.04B | - | -% | -7.3% | $14.39 | Compare |
TMDX
TransMedics Group, Inc.
BULLISH
Mkt Cap
$3.9B
P/E
23.3
ROE
54.2%
Price
$113.13
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-04 | LOVELL STEPHANIE | Director | Sale | 1,193 | $178,497 |
| 2026-03-04 | HERNANDEZ GERARDO | Chief Financial Officer | Sale | 7,611 | $1,117,382 |
| 2026-03-04 | HERNANDEZ GERARDO | Chief Financial Officer | Option Exercise | 7,236 | $515,001 |
| 2026-03-04 | WEILL DAVID | Director | Sale | 3,571 | $524,294 |
| 2026-03-04 | WEILL DAVID | Director | Option Exercise | 3,571 | $50,708 |
| 2026-03-02 | CORCORAN NICHOLAS | Officer | Sale | 2,966 | $412,630 |
| 2026-03-02 | RANGANATH ANIL P | General Counsel | Sale | 864 | $120,200 |
| 2026-02-18 | CECERE GIOVANNI | Officer | Stock Award | 11,082 | - |
| 2025-12-04 | HERNANDEZ GERARDO | Chief Financial Officer | Sale | 920 | $128,450 |
| 2025-12-03 | WEILL DAVID | Director | Sale | 5,000 | $693,200 |
| 2025-12-03 | WEILL DAVID | Director | Option Exercise | 5,000 | $71,000 |
| 2025-11-25 | RANGANATH ANIL P | General Counsel | Sale | 3,000 | $435,660 |
| 2025-11-25 | RANGANATH ANIL P | General Counsel | Option Exercise | 3,000 | $281,640 |
| 2025-11-17 | HASSANEIN WALEED H | Chief Executive Officer | Purchase | 8,775 | $1,000,350 |
| 2025-10-29 | BASILE EDWARD M. | Director | Sale | 4,142 | $540,324 |
LOVELL STEPHANIE
Director
2026-03-04
1,193 shares
·
$178,497
HERNANDEZ GERARDO
Chief Financial Officer
2026-03-04
7,611 shares
·
$1,117,382
HERNANDEZ GERARDO
Chief Financial Officer
2026-03-04
7,236 shares
·
$515,001
WEILL DAVID
Director
2026-03-04
3,571 shares
·
$524,294
WEILL DAVID
Director
2026-03-04
3,571 shares
·
$50,708
CORCORAN NICHOLAS
Officer
2026-03-02
2,966 shares
·
$412,630
RANGANATH ANIL P
General Counsel
2026-03-02
864 shares
·
$120,200
CECERE GIOVANNI
Officer
2026-02-18
11,082 shares
HERNANDEZ GERARDO
Chief Financial Officer
2025-12-04
920 shares
·
$128,450
WEILL DAVID
Director
2025-12-03
5,000 shares
·
$693,200
WEILL DAVID
Director
2025-12-03
5,000 shares
·
$71,000
RANGANATH ANIL P
General Counsel
2025-11-25
3,000 shares
·
$435,660
RANGANATH ANIL P
General Counsel
2025-11-25
3,000 shares
·
$281,640
HASSANEIN WALEED H
Chief Executive Officer
2025-11-17
8,775 shares
·
$1,000,350
BASILE EDWARD M.
Director
2025-10-29
4,142 shares
·
$540,324
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
DEF 14A
8-K
10-K
TransMedics Group, Inc. (TMDX) filed its annual 10-K report on February 24, 2026. While specific financial metrics and risk details were not provided in the excerpts, the filing includes comprehensive disclosures regarding the company's business operations, risk factors, and management's analysis of its financial condition.
8-K
8-K
10-Q
8-K
10-Q
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
10 analysts
Evercore ISI Group
2026-04-06
Outperform
Outperform
Stifel
2026-03-09
Hold
Hold
JP Morgan
2026-02-25
Neutral
Neutral
Oppenheimer
2026-02-25
Outperform
Outperform
Piper Sandler
2026-02-25
Overweight
Overweight
Evercore ISI Group
2026-02-25
Outperform
Outperform
Needham
2026-02-25
Buy
Buy
Canaccord Genuity
2025-12-17
Buy
Buy
Needham
2025-12-08
Buy
Buy
Morgan Stanley
2025-12-02
Equal-Weight
Equal-Weight
Past News Coverage
Recent headlines mentioning TMDX from our newsroom.
Newest → oldest
No matching news yet.